Reference to the research and release world "2018 China cannabis diphenol industry analysis report - market operation situation and investment prospects"

        Cannabinol (CBD) is the main chemical component of medicinal plant cannabis. It is extracted from female cannabis plants and is a non-addictive component in cannabis. It has anti-tuberculosis, anti-anxiety, anti-inflammatory and other pharmacological effects.

        The CBD was first isolated from Adams and Todd in Mexico and Indian cannabis in 1940, but due to the limitations of experimental conditions at the time, errors in the determination of the CBD structure occurred. Knowing that in 1963, Mechoulam and Shvo determined their exact chemical structure, which is the current CBD structure. Since then, Santavy gave the three-dimensional structure of the CBD in 1964 and published its related data; Jones determined the crystal structure of the CBD in 1977, and reported two independent three-dimensional structures of the CBD. The plant cannabis is (-) - The CBD form exists.

Three-dimensional structure of CBD
Source: Public information

        The CBD is classified into two types according to the use and can be classified into a consumer type CBD and a medical type CBD. Consumer CBDs can be added to food and beverages for consumption. Medical CBD can be used to treat diseases such as epilepsy and Parkinson's disease.

        The upstream industry of the cannabisdiol industry is cannabis cultivation, and the downstream industries are mainly the medical industry and the food industry.

Cannabisdiol industry chain structure
Source: Guanyan Tianxia Data Center

        Cannabisdiol is in an important position in the industrial chain, but its raw material supply is entirely from cannabis, so it is very dependent on the supply of upstream raw materials. According to the National Bureau of Statistics, China's cannabis production in 2016 was 77,000 tons, an increase of 50,000 tons compared with 2015. , an increase of 185%. This provides a sufficient raw material basis for the production and extraction of cannabisdiol in China. For the downstream, 80% of China's cannabis is used in the pharmaceutical industry, mainly in the Chinese herbal medicine industry. Although the CBD has already achieved mass production, the current production capacity is relatively serious, and the downstream market has not yet opened.

        China is the world's major cannabis planting area. With the gradual planning of China's cannabis industry, Yunnan has already applied for legal cannabis cultivation. Heilongjiang has also issued a request for legal cannabis cultivation. Several marijuana producing areas are proactive and promising. Let the cannabis planting industry in China enter into large-scale and intensive development, thus driving the supply of cannabisdiol products.

Domestic industrial cannabis production forecast for 2018-2024
Source: Guanyan Tianxia Data Center

        In recent years, China's cannabisdiol industry has achieved mass production through the efforts of scientific researchers. At the same time, the application of cannabidiol in China has begun to be promoted. More and more biopharmaceutical companies are beginning to realize the medicinal value of cannabidiol. The raw material for cannabisdiol is industrial cannabis, so the industry is regulated by the government, and only companies licensed by the government can legally produce cannabidiol.

        At present, China's cannabisdiol industry is in the naive development period of the industry. The domestic cannabisdiol market is mainly imported, and the domestic enterprises are only Hansui, and there are not many small-volume production enterprises. For the downstream market, most of the products currently circulating in the market are small doses, with g and mg as purchasing units, and there are almost no large-volume buyers.

        By the end of 2017, the market size of China's cannabisdiol industry has reached 448 million yuan, and it is expected to reach 547 million yuan in 2018. details as follows:

China's cannabis diphenol industry market scale in 2013-2018
Source: Guanyan Tianxia Data Center

        At present, the regional distribution of China's cannabisdiol industry market is as follows. Among them, East China is the largest market for cannabisdiol industry, with a market share of 34.1%, South China accounting for 12.4%, and North China accounting for 14.2%. details as follows:

Regional distribution of Chinese cannabisdiol industry market in 2017
Source: Guanyan Tianxia Data Center

        With the increasing use of products made from cannabisdiol, the market size of the industry will continue to grow. In particular, its medicinal value, China's aging population has reached 200 million, the number of slow patient groups is huge, the economic level is improved, and the progress of medical technology has made the demand for medical care of Chinese people increase. Great health extends the connotation of medical care from the traditional disease to prevention and rehabilitation. Even people's food, clothing, housing, transportation, life and death, attention to various risk factors and complete health affecting health. On the 19th National Congress, healthy China has once again risen to the country. strategy. Therefore, the medicinal value of cannabidiol is of great significance to China, and its market will expand rapidly with the gradual time of product function.

        The medicinal value of cannabisdiol is gradually tapping, and its market size will continue to grow. It is expected that its market size will reach 1.8 billion yuan by 2024.

Prediction of the market size of cannabisdiol in 2018-2024
Source: Guanyan Tianxia Data Center

Source: Guanyan World, reprint, please indicate the source. (ww)